Originally generalized epilepsy with typical and unusual attacks of the unconscious.
Composition:
1 capsule contains 250 mg of ethosuximide.
Action:
An anticonvulsant, especially effective in the treatment of seizures of the unconscious. The product contains an active substance that inhibits thalamic neurons and probably acts to stimulate thalamocortical circuits. It inhibits the formation of seizures of the unconscious, but does not affect other types of seizures. The drug is absorbed quickly and completely from the digestive tract. The maximum concentration in the blood occurs after 1-4 h. The concentration in the cerebrospinal fluid approximately corresponds to the concentration in the serum. Plasma protein binding is below 10%. It is excreted by the kidneys, 20% unchanged, the rest in the form of inactive metabolites. T0,5 in plasma is 48-60 hours in adults and 16-58 hours in children.
Contraindications:
Hypersensitivity to ethosuximide or other succinimides or other components of the preparation.
Precautions:
Caution should be exercised in patients with renal or hepatic dysfunction. In order to avoid major seizures with concomitant pancreatic collapse and if generalized seizures or EEG-associated seizures occur, the product should be given in combination with other anticonvulsant medicines affecting this type of epilepsy.
Pregnancy and lactation:
Pregnant should be used if the anticipated benefits outweigh the potential risks to the fetus and mother. Dosing during pregnancy should be kept as low as possible, especially up to 40 days of pregnancy. It is best to use monotherapy when pregnant. The concentration of ethosuximide in human milk is close to that in serum.
Side effects:
In the initial period of treatment: nausea, vomiting, anorexia, gastric pains, weight loss, diarrhea, fatigue, headache and dizziness, ataxia, photophobia. In rare cases, sleep disorders, impaired concentration, hiccups, proteinuria, urticaria, rash, Stevens-Johnson syndrome, systemic lupus erythematosus, scleroderma, hirsutism, parkinsonian syndrome, irritability, agitation, aggression, myopia, and vaginal bleeding may occur. , swelling of the tongue and palate, increased glutamine-oxalactic transaminase and urobilinogen, leukopenia, agranulocytosis, thrombocytopenia, eosinophilia, aplastic anemia.
Dosage:
Orally. Dosage should be determined individually. The following scheme is proposed (general guidelines): adults: in 1 week of treatment - 2 capsules per day, in 2 weeks - 4 capsules, in 3 weeks - 6 capsules, in 4 weeks 6-8 capsules. Children in school age (from 6 years of age): in 1 week of treatment - 1 capsule per day, in 2 weeks - 2 capsules, in 3 weeks - 4 capsules, in 4 weeks - 4-6 capsules Children from 3 to 6 years of age: 1 week of treatment 1 capsule a day, in 2 weeks - 2 capsules, in 3 weeks - 3 capsules, in 4 weeks - 3 capsules. Special care should be taken with doses above 750-1000 mg in children and over 1500 mg in adults. Maintenance doses are usually 20 mg / kg. in children and 15 mg / kg in adults. In patients with severe renal insufficiency with a creatinine clearance below 10 ml / min, the dose should be reduced. The total daily dose is usually divided into two doses. The therapeutic concentration in the serum is about 40-100 mg / l (280-700 μmol / l). Kaps. should be swallowed whole with a sufficient amount of liquid, taken with food.
(C)
